VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

NASDAQ:VNDA • US9216591084

6.2 USD
+0.11 (+1.81%)
At close: Feb 17, 2026
6.25 USD
+0.05 (+0.81%)
After Hours: 2/17/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, VNDA scores 2 out of 10 in our fundamental rating. VNDA was compared to 521 industry peers in the Biotechnology industry. VNDA has a bad profitability rating. Also its financial health evaluation is rather negative. VNDA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • VNDA had negative earnings in the past year.
  • VNDA had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: VNDA reported negative net income in multiple years.
  • In multiple years VNDA reported negative operating cash flow during the last 5 years.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

  • VNDA has a better Return On Assets (-14.01%) than 81.00% of its industry peers.
  • Looking at the Return On Equity, with a value of -18.07%, VNDA belongs to the top of the industry, outperforming 84.64% of the companies in the same industry.
Industry RankSector Rank
ROA -14.01%
ROE -18.07%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • VNDA has a Gross Margin of 94.44%. This is amongst the best in the industry. VNDA outperforms 95.01% of its industry peers.
  • VNDA's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VNDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • VNDA has an Altman-Z score of 1.19. This is a bad value and indicates that VNDA is not financially healthy and even has some risk of bankruptcy.
  • VNDA's Altman-Z score of 1.19 is fine compared to the rest of the industry. VNDA outperforms 64.30% of its industry peers.
  • VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.01, VNDA perfoms like the industry average, outperforming 46.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.19
ROIC/WACCN/A
WACC8.65%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

  • VNDA has a Current Ratio of 3.12. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 3.12, VNDA is not doing good in the industry: 62.96% of the companies in the same industry are doing better.
  • A Quick Ratio of 3.10 indicates that VNDA has no problem at all paying its short term obligations.
  • VNDA's Quick ratio of 3.10 is on the low side compared to the rest of the industry. VNDA is outperformed by 60.65% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 3.1
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for VNDA have decreased strongly by -462.50% in the last year.
EPS 1Y (TTM)-462.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.58%

3.2 Future

  • Based on estimates for the next years, VNDA will show a very strong growth in Earnings Per Share. The EPS will grow by 25.50% on average per year.
  • Based on estimates for the next years, VNDA will show a decrease in Revenue. The Revenue will decrease by -2.33% on average per year.
EPS Next Y17.97%
EPS Next 2Y25.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.49%
Revenue Next 2Y26.68%
Revenue Next 3Y24.31%
Revenue Next 5Y-2.33%

3.3 Evolution

VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
  • Also next year VNDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • VNDA's earnings are expected to grow with 25.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.5%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (2/17/2026, 8:00:02 PM)

After market: 6.25 +0.05 (+0.81%)

6.2

+0.11 (+1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)05-05
Inst Owners78.35%
Inst Owner Change3.44%
Ins Owners7.03%
Ins Owner Change0%
Market Cap366.42M
Revenue(TTM)N/A
Net Income(TTM)-84.20M
Analysts80
Price Target13.9 (124.19%)
Short Float %6.04%
Short Ratio1.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.31%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.82%
EPS beat(4)3
Avg EPS beat(4)8.92%
Min EPS beat(4)-26.44%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)-4.56%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.83%
Min Revenue beat(2)-6.09%
Max Revenue beat(2)-5.56%
Revenue beat(4)1
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-6.09%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)1.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.96%
PT rev (3m)7.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.66%
EPS NY rev (1m)-15.82%
EPS NY rev (3m)-49.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.73
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS3.59
BVpS7.88
TBVpS6.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.01%
ROE -18.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.44%
FCFM N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.83%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 3.1
Altman-Z 1.19
F-Score3
WACC8.65%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-462.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y17.97%
EPS Next 2Y25.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.58%
Revenue Next Year22.49%
Revenue Next 2Y26.68%
Revenue Next 3Y24.31%
Revenue Next 5Y-2.33%
EBIT growth 1Y-223.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-425.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-415.99%
OCF growth 3YN/A
OCF growth 5YN/A

VANDA PHARMACEUTICALS INC / VNDA FAQ

What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VNDA.


What is the valuation status of VANDA PHARMACEUTICALS INC (VNDA) stock?

ChartMill assigns a valuation rating of 1 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.


What is the profitability of VNDA stock?

VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 3 / 10.


Can you provide the financial health for VNDA stock?

The financial health rating of VANDA PHARMACEUTICALS INC (VNDA) is 3 / 10.


What is the expected EPS growth for VANDA PHARMACEUTICALS INC (VNDA) stock?

The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to grow by 17.97% in the next year.